Urelumab

Urelumab is a humanized agonistic monoclonal antibody designed for the treatment of cancer and solid tumors.

Urelumab targets the CD137 receptor. It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. Synonyms include BMS-663513 and anti-4-1BB monoclonal antibody

Urelumab/BMS-663513 was developed by Bristol-Myers Squibb.